As filed with the Securities and Exchange
Commission on March 24, 2017
Registration No.
333-_________
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_________________
FORM S-3
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
Lakeland Industries, Inc.
(Exact name of registrant as specified
in its charter)
|
Delaware
|
|
13-3115216
|
|
(State or other jurisdiction of
|
|
(I.R.S. Employer
|
|
incorporation or organization)
|
|
Identification No.)
|
3555 Veterans Memorial Highway, Suite
C
Ronkonkoma, New York 11779
(631) 981-9700
(Address, including zip code, and telephone
number, including area code,
of registrant’s principal executive
offices)
Christopher J. Ryan
Chief Executive Officer and President
Lakeland Industries, Inc.
3555 Veterans Memorial Highway, Suite
C
Ronkonkoma, New York 11779
(631) 981-9700
(Name, address, including zip code, and
telephone number, including area code, of agent for service)
Copies to:
Gary T. Moomjian, Esq.
Jill T. Braunstein, Esq.
Moomjian, Waite & Coleman, LLP
100 Jericho Quadrangle, Suite 208
Jericho, New York 11753
Ph: (516) 937-5900
Fax: (516) 937-5050
Approximate date of commencement of proposed sale to the
public:
From time to time after the effective date of this Registration Statement.
If the only securities being registered on this form are being
offered pursuant to dividend or interest reinvestment plans, please check the following box.
¨
If any of the securities being registered on this Form are to
be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered
only in connection with dividend or interest reinvestment plans, check the following box.
x
If this form is filed to register additional securities for
an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration
statement number of the earlier effective registration statement for the same offering.
¨
If this form is a post-effective amendment filed pursuant to
Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the
earlier effective registration statement for the same offering.
¨
If this form is a registration statement pursuant to General
Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to
Rule 462(e) under the Securities Act, check the following box.
¨
If this form is a post-effective amendment to a registration
statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities
pursuant to Rule 413(b) under the Securities Act, check the following box.
¨
Indicate by check mark whether the registrant is a large accelerated
filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated
filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check
one):
|
Large accelerated filer
¨
|
Accelerated filer
¨
|
|
|
|
|
Non-accelerated filer
¨
|
Smaller reporting company
x
|
|
(Do not check if a smaller reporting company)
|
|
CALCULATION OF REGISTRATION FEE
|
TITLE OF EACH CLASS OF
SECURITIES TO BE
REGISTERED
|
|
AMOUNT TO BE REGISTERED(1)
|
|
|
PROPOSED MAXIMUM OFFERING
PRICE PER
UNIT
|
|
|
PROPOSED MAXIMUM AGGREGATE OFFERING
PRICE(2)
|
|
|
AMOUNT OF REGISTRATION
FEE(3)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common Stock, $.01 par value
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Preferred Stock, $.01 par value
Debt Securities
Warrants
Rights
Units
Total
|
|
|
|
|
|
|
|
|
|
$
|
30,000,000
|
|
|
$
|
3,477
|
|
|
|
(1)
|
There are being registered hereunder an unspecified number or aggregate
principal amount, as applicable, of (i) shares of common stock, (ii) shares of preferred
stock, (iii) debt securities, (iv) warrants to purchase common stock, preferred stock,
debt securities, and/or units, (v) rights to purchase common stock, preferred stock,
debt securities, warrants and/or units, and (vi) units of two or more of the securities
described herein, all at indeterminate prices, as shall have an aggregate initial offering
price not to exceed $30,000,000. If any debt securities are issued at an original issue
discount, then the offering price of such debt securities shall be equal to any such
greater principal amount due at maturity, such aggregate principal amount not to exceed
$30,000,000 less the aggregate dollar amount of securities previously issued hereunder.
Any securities registered under this registration statement may be sold separately or
in combination with the other securities registered hereunder. The securities registered
also include such indeterminate number of securities that may be issued upon exercise,
conversion or exchange of any securities registered hereunder that provide for exercise,
conversion or exchange or pursuant to the antidilution provisions of any such securities.
In addition, pursuant to Rule 416 under the Securities Act of 1933, as amended (the “Securities
Act”), the securities being registered hereunder also include such indeterminate
number of securities as may be issuable with respect to the securities being registered
hereunder as a result of stock splits, stock dividends, recapitalizations, or similar
transactions. As of March 23, 2017, the aggregate market value of the registrant’s
outstanding common stock held by non-affiliates was approximately $67,436,823 based on
6,716,815 shares held by non-affiliates and a per share price of $10.04. Pursuant to
General Instruction I.B.6 of Form S-3, in no event will we sell securities pursuant to
this prospectus with a value of more than one-third of the aggregate market value of
our common stock held by non-affiliates in any twelve-month period, so long as the aggregate
market value of our common stock held by non-affiliates is less than $75,000,000. In
the event that subsequent to the date of this prospectus, the aggregate market value
of our outstanding common stock held by non-affiliates equals or exceeds $75,000,000,
then the one-third limitation on sales shall not apply to additional sales made pursuant
to this prospectus. The registrant has not offered any securities pursuant to General
Instruction I.B.6 of Form S-3 during the twelve calendar months prior to and including
the date of this prospectus.
|
|
|
(2)
|
The proposed maximum aggregate offering price per class of security will be determined from time to time by the registrant
in connection with the issuance by the registrant of the securities registered hereunder and is not specified as to each class
of security pursuant to General Instruction II.D of Form S-3 under the Securities Act.
|
|
|
(3)
|
The registration fee has been calculated pursuant to Rule 457(o) under the Securities Act.
|
THE REGISTRANT HEREBY AMENDS THIS REGISTRATION STATEMENT ON
SUCH DATE OR DATES AS MAY BE NECESSARY TO DELAY ITS EFFECTIVE DATE UNTIL THE REGISTRANT SHALL FILE A FURTHER AMENDMENT WHICH SPECIFICALLY
STATES THAT THIS REGISTRATION STATEMENT SHALL THEREAFTER BECOME EFFECTIVE IN ACCORDANCE WITH SECTION 8(A) OF THE SECURITIES ACT
OF 1933, AS AMENDED, OR UNTIL THE REGISTRATION STATEMENT SHALL BECOME EFFECTIVE ON SUCH DATE AS THE COMMISSION, ACTING PURSUANT
TO SAID SECTION 8(A), MAY DETERMINE.
SUBJECT TO COMPLETION, DATED MARCH 24, 2017
The information in this prospectus is not complete and may be
changed. These securities may not be sold until the registration statement filed with the Securities and Exchange Commission relating
to these securities is effective. This prospectus is not an offer to sell these securities and it is not soliciting an offer to
buy these securities in any state where the offer or sale is not permitted.
PROSPECTUS
LAKELAND INDUSTRIES, INC.
$30,000,000
Common Stock
Preferred Stock
Debt Securities
Warrants
Rights
Units
We may offer to the public from time to time in one or more
series or issuances at prices and on terms that we will determine at the time of each offering, shares of our common stock; shares
of preferred stock; debt securities; warrants to purchase shares of our common stock, preferred stock, debt securities and/or units;
rights to purchase common stock, preferred stock, debt securities, warrants and/or units; and units consisting of any of the foregoing,
each as described in this prospectus. This prospectus also covers an indeterminate number of securities that may be issued upon
exercise, conversion or exchange of any securities registered hereunder that provide for exercise, conversion or exchange or pursuant
to the antidilution provisions of any such securities. The aggregate initial offering price of all securities sold by us pursuant
to this prospectus will not exceed $30,000,000.
This prospectus describes the general manner in which our securities
may be offered using this prospectus. Each time we offer and sell securities, we will provide you with a prospectus supplement
that will contain specific information about the terms of that offering. Any prospectus supplement may also add, update, or change
information contained in this prospectus. You should carefully read this prospectus and the applicable prospectus supplement, as
well as the documents incorporated or deemed to be incorporated by reference in this prospectus before you purchase any of the
securities offered hereby. This prospectus may not be used to consummate a sale of securities unless accompanied by a prospectus
supplement.
We may offer the securities directly or through agents or to
or through underwriters or dealers. If any agents or underwriters are involved in the sale of the securities, their names and any
applicable purchase price, fee, commission or discount arrangement between or among them, will be set forth, or will be calculable
from the information set forth, in an accompanying prospectus supplement. The securities may be offered and sold through public
or private transactions at market prices prevailing at the time of sale, at a fixed price or fixed prices, at negotiated prices,
at various prices determined at the time of sale or at prices related to prevailing market prices. We can sell the securities through
agents, underwriters or dealers only with delivery of a prospectus supplement describing the method and terms of the offering of
such securities. In addition, shares of our common stock may be offered from time to time through ordinary brokerage transactions
on The NASDAQ Global Market. See “Plan of Distribution.”
Our common stock is currently traded on The NASDAQ Global Market
under the symbol “LAKE.” On March 23 2017, the closing price of our common stock was $10.04 per share. As of March
23, 2017, the aggregate market value of our outstanding common stock held by non-affiliates was approximately $67,436,823, based
on 7,263,774 shares of outstanding common stock, of which 6,716,815 shares were held by non-affiliates, and a per share price
of $10.04 based on the closing sale price of our common stock as of March 23, 2017. Pursuant to General Instruction I.B.6 of Form
S-3, in no event will we sell securities pursuant to this prospectus with a value of more than one-third of the aggregate market
value of our common stock held by non-affiliates in any twelve-month period, so long as the aggregate market value of our common
stock held by non-affiliates is less than $75,000,000. In the event that subsequent to the date of this prospectus, the aggregate
market value of our outstanding common stock held by non-affiliates equals or exceeds $75,000,000, then the one-third limitation
on sales shall not apply to additional sales made pursuant to this prospectus. We have not offered any securities pursuant to
General Instruction I.B.6 of Form S-3 during the twelve calendar months prior to and including the date of this prospectus.
Investing in our securities involves a high degree of risk.
You should carefully read the section entitled “Risk Factors” on page 5 of this prospectus and in any prospectus supplement,
as well as in any of the documents incorporated or deemed to be incorporated by reference in this prospectus before purchasing
any securities offered by this prospectus.
Neither the Securities and Exchange Commission nor any state
securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete.
Any representation to the contrary is a criminal offense.
This prospectus is dated , 2017
TABLE OF CONTENTS
ABOUT THIS PROSPECTUS
You should rely only on the information
contained in this prospectus, any prospectus supplement and the documents incorporated by reference in this prospectus. We have
not authorized anyone to provide you with different information. No dealer, salesperson or other person is authorized to give you
any written information other than this prospectus or any prospectus supplement, or to make representations as to matters not stated
in this prospectus or any prospectus supplement. This prospectus and any prospectus supplement do not constitute an offer to sell
these securities and are not soliciting offers to buy these securities in any jurisdiction where the offer or sale of these securities
is not permitted. You should not assume that the information contained in this prospectus is accurate as of any date other than
the date on the front cover of this prospectus, or that the information contained in any prospectus supplement or any document
incorporated by reference is accurate as of any date other than the date of the prospectus supplement or the document incorporated
by reference, regardless of the time of delivery of this prospectus or any sale of securities.
This prospectus is part of a registration
statement that we filed with the Securities and Exchange Commission, or SEC, using a “shelf” registration process.
Under this shelf registration process, we may sell any of the securities, or any combination of the securities, described in this
prospectus, in each case in one of more offerings up to a total dollar amount of proceeds of $30,000,000, subject to securities
laws limitations. This prospectus describes the general manner in which our securities may be offered by this prospectus. Each
time we sell securities, we will provide a prospectus supplement that will contain specific information about the terms of those
securities and terms of that offering. The prospectus supplement may also add, update or change information contained in this prospectus
or in documents incorporated by reference in this prospectus. To the extent that any statement that we make in a prospectus supplement
is inconsistent with statements made in this prospectus or in documents incorporated by reference in this prospectus, you should
rely on the information in the prospectus supplement. You should carefully read this prospectus and any applicable prospectus supplement,
together with the information incorporated by reference as described under the below sections titled “Where You Can Find
More Information” and “Information Incorporated by Reference” before buying any securities in this offering.
Unless otherwise indicated, all references
in this prospectus to “$” or “dollars” are to U.S. dollars and financial information presented in this
prospectus that is derived from financial statements incorporated by reference is prepared in accordance with accounting principles
generally accepted in the United States.
As used in this prospectus, unless the context
requires otherwise, references to “Lakeland,” “the Company,” “we,” “us,” or “our”
refer to Lakeland Industries, Inc. and its subsidiaries.
PROSPECTUS SUMMARY
This summary highlights important information
about our business and about this prospectus. This summary does not contain all of the information that may be important to you.
You should carefully read this prospectus in its entirety before making an investment decision. In particular, you should read
the section entitled “Risk Factors” and the information referred to therein and the financial statements and related
notes incorporated by reference in this prospectus.
Corporate Information
We are a corporation organized under the
laws of the State of Delaware. Our principal executive offices are located at 3555 Veterans Memorial Highway, Suite C, Ronkonkoma,
NY 11779, our telephone number is (631) 981-9700 and our website is located at www.lakeland.com. The contents of our website
are not part of this prospectus.
Our Business
We manufacture and sell a comprehensive
line of safety garments and accessories for the industrial protective clothing market. Our products are sold by our in-house customer
service group, our regional sales managers and independent sales representatives to a network of over 1,200 North American safety
and mill supply distributors. These distributors in turn supply end user industrial customers, such as integrated oil, chemical/petrochemical,
utilities, automobile, steel, glass, construction, smelting, munition plants, janitorial, pharmaceutical, mortuaries and high technology
electronics manufacturers, as well as scientific and medical laboratories. In addition, we supply to federal, state and local governmental
agencies and departments, such as fire and law enforcement, airport crash rescue units, the Department of Defense, the Department
of Homeland Security and the Centers for Disease Control. Internationally, sales are to a mixture of end users directly and industrial
distributors depending on the particular country market. Sales are made to more than 40 foreign countries but are primarily in
China, European Economic Community (“EEC”), Canada, Chile, Argentina, Russia, Colombia, Mexico, Ecuador and Southeast
Asia.
The Securities We May Offer
We may offer and sell from time to time
any of the following securities up to a total value of $30,000,000 under this prospectus, together with any applicable prospectus
supplement, at prices and on terms to be determined by market conditions at the time of the offering:
|
|
•
|
shares of our common stock;
|
|
|
•
|
shares of our preferred stock;
|
|
|
•
|
debt securities consisting of convertible debentures,
notes or other evidences of indebtedness;
|
|
|
•
|
warrants to purchase shares of our common stock, preferred
stock, debt securities and/or units;
|
|
|
•
|
rights to purchase our common stock, preferred stock,
debt securities, warrants and/or units; and
|
|
|
•
|
units consisting of any combination of securities offered
under this prospectus.
|
This prospectus provides you with a general
description of the securities we may offer. When particular securities are offered, we will provide a prospectus supplement that
will describe the specific amounts, prices and other important terms of the offered securities. A prospectus supplement and any
related free writing prospectus that we may provide to you may also add, update, or change information contained in this prospectus
or in documents we have incorporated by reference. However, no prospectus supplement will offer a security that is not registered
and described in this prospectus at the time of the effectiveness of the registration statement of which this prospectus is a part.
RISK FACTORS
Investing in our securities involves risks.
You should carefully review the risks and uncertainties described under the heading “Risk Factors” contained in our
most recent Annual Report on Form 10-K, or any updates in our Quarterly Reports on Form 10-Q, together with all of the other information
appearing in this prospectus or incorporated by reference into this prospectus and any applicable prospectus supplement, in light
of your particular investment objectives and financial circumstances. The risks so described are not the only risks facing our
company. There may be other unknown or unpredictable economic, business, competitive, regulatory or other factors that could have
material adverse effects on our future results. Past financial performance may not be a reliable indicator of future performance
and historical trends should not be used to anticipate results or trends in future periods. Our business, financial condition and
results of operations could be materially adversely affected by any of these risks. In that event, the market price of our securities
could decline and you could lose all or part of your investment. You should carefully consider all of the information set forth
in this prospectus, any prospectus supplement, and the documents incorporated by reference herein and therein and annexed hereto
and thereto with your respective legal counsel, tax and financial advisors and/or accountants prior to purchasing our securities.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING
STATEMENTS
This prospectus and the information incorporated
by reference in this prospectus contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933,
as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934 (the “Exchange Act”).
These forward-looking statements involve risks, uncertainties and assumptions as described in registration statements, annual reports
and other periodic reports and filings we file from time to time with the SEC. Such statements may relate to our strategy, future
operations, future financial position, future revenues, projected costs, and plans and objectives of management. All statements
contained herein or incorporated by reference in this prospectus that are not clearly historical in nature are forward-looking,
and the words “anticipate,” “believe,” “continues,” “expect,” “estimates,”
“intend,” “project” and similar expressions, as well as statements in future tense, identify forward-looking
statements.
We caution readers that these forward-looking
statements are not a guarantee of future performance. Actual results could differ materially from any expectation, estimate or
projection conveyed by these statements and there can be no assurance that any such expectation, estimate or projection will be
met. Numerous important factors, risks and uncertainties affect our operating results and could cause actual results to differ
from the results implied by these or any other forward-looking statements. These potential factors, risks and uncertainties include,
among other things, such factors as:
|
|
•
|
our ability to obtain additional funds, if necessary;
|
|
|
•
|
we are subject to risk as a result of our international manufacturing operations;
|
|
|
•
|
our results of operations could be negatively affected by potential fluctuations in foreign currency exchange rates;
|
|
|
•
|
we deal in countries where corruption is an obstacle;
|
|
|
•
|
we have experienced material weaknesses in internal controls in the past and although we believe such weaknesses have been
remediated, there can be no assurance that such weaknesses will not occur in the future;
|
|
|
•
|
there is no assurance that our disposition of our Brazilian subsidiary will be entirely successful in that we may continue
to be exposed to certain liabilities in connection with the operations of such company. In addition, while our tax advisors believe
that the worthless stock deduction taken by our company in connection therewith is valid, there can be no assurance that the IRS
will not challenge it and, if challenged, that we will prevail;
|
|
|
•
|
rapid technological change could negatively affect sales of our products, inventory levels and our performance;
|
|
|
•
|
we must estimate customer demand because we do not have long-term commitments from many of our customers, and errors in our
estimates could negatively impact our inventory levels and net sales;
|
|
|
•
|
our operations are substantially dependent upon key personnel;
|
|
|
•
|
we rely on a limited number of suppliers and manufacturers for specific fabrics, and we may not be able to obtain substitute
suppliers and manufacturers on terms that are as favorable, or at all, if our supplies are interrupted;
|
|
|
•
|
our inability to protect our intellectual property;
|
|
|
•
|
our effective tax rate could change as a result of tax reform and the result could be a significant one-time noncash charge
to tax expense in order to adjust our deferred tax asset;
|
|
|
•
|
we face competition from other companies, a number of which have substantially greater resources than we do;
|
|
|
•
|
our overall sales volume has recently been reduced due to global softness in the industrial sector partially resulting from
a continuing downturn in the oil and gas industry and there can be no assurance that such downturn will not continue in the future;
|
|
|
•
|
some of our sales are to foreign buyers, which exposes us to additional risks;
|
|
|
•
|
a significant reduction in government funding for preparations for terrorist incidents could adversely affect our net sales;
|
|
|
•
|
we may be subject to product liability claims, and insurance coverage could be inadequate or unavailable to cover these claims;
|
|
|
•
|
our directors and executive officers have the ability to exert significant influence on us and on matters subject to a vote
of our stockholders;
|
|
|
•
|
our failure to realize anticipated benefits from acquisitions, divestitures or restructurings, or the possibility that such
acquisitions, divestitures or restructurings could adversely affect us;
|
|
|
•
|
our ability to make payments on our indebtedness and comply with the restrictive covenants therein;
|
|
|
•
|
covenants in our credit facilities may restrict our financial and operating flexibility;
|
|
|
•
|
other risks and uncertainties, including those mentioned in the documents incorporated by reference herein, including our most
recent Annual Report on Form 10-K, as such may be amended or supplemented (see “Risk Factors”).
|
You should carefully consider such risks,
uncertainties and other information, disclosures and discussions which contain cautionary statements identifying important factors
that could cause actual results to differ materially from those provided in the forward-looking statements.
Except as may be required, we undertake
no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events
or otherwise.
This discussion should be read in conjunction
with the consolidated financial statements and notes thereto incorporated by reference in this prospectus.
USE OF PROCEEDS
We will retain broad discretion over the
use of the net proceeds from the sale of our securities offered by us hereby. Except as described in any prospectus supplement,
we currently intend to use the net proceeds from the sale of securities offered by us pursuant to this prospectus for working capital,
capital expenditures, investments in our subsidiaries, and other general corporate purposes. We may also use such proceeds to fund
acquisitions of businesses, technologies, or product lines that complement our current business. However, we currently have no
commitments or agreements for any specific acquisitions. Pending application of the net proceeds, we intend to utilize the net
proceeds to temporarily pay down our revolving line of credit and/or invest the net proceeds of the offering of securities by us
in investment-grade, interest-bearing securities.
The intended application of proceeds from
the sale of any particular offering of securities using this prospectus will be described in the accompanying prospectus supplement
relating to such offering. The precise amount and timing of the application of these proceeds will depend on our funding requirements
and the availability and costs of other funds.
DESCRIPTION OF OUR CAPITAL STOCK
The following description of the material
terms of our capital stock includes a summary of specified provisions of our restated certificate of incorporation and amended
and restated bylaws. This description also summarizes relevant provisions of the Delaware General Corporation Law, or “DGCL.”
The terms of our restated certificate of incorporation and amended and restated bylaws, and the DGCL are more detailed than the
general information below. Therefore, please carefully consider the actual provisions of these documents, which have been filed
with the SEC as exhibits to the registration statement of which this prospectus forms a part, and the DGCL.
Authorized Capital
Our authorized capital consists of:
|
|
•
|
10,000,000 shares of common stock, $0.01 par value per share, of which 7,263,774 shares are outstanding
as of March 24, 2017; and
|
|
|
•
|
1,500,000 shares of preferred stock, $0.01 par value per share, none of which shares are outstanding.
|
Common Stock
The holders of our common stock (i) have
equal ratable rights to dividends from funds legally available therefor, when and if declared by our Board of Directors; (ii) are
entitled to share in all of our assets available for distribution to holders of common stock upon liquidation, dissolution or winding
up of our affairs; (iii) do not have preemptive, subscription or conversion rights and there are no redemption or sinking fund
provisions or rights; and (iv) are entitled to one non-cumulative vote per share on all matters on which stockholders may vote.
Holders of shares
of our common stock do not have cumulative voting rights, which means that the holders of more than 50% of the outstanding shares,
voting for the election of directors, can elect all of the directors to be elected, if they so choose, and, in such event, the
holders of the remaining shares will not be able to elect any of our directors.
We
currently intend to retain our future earnings, if any, for use in our business and therefore do not anticipate paying cash dividends
in the foreseeable future. Payment of future dividends, if any, will be at the discretion of our Board after taking into account
various factors, including our financial condition, operating results, and current and anticipated cash needs. In addition, our
ability to pay dividends is subject to certain contractual restrictions imposed by our current senior financing facility.
Preferred Stock
Under
our certificate of incorporation, our board of directors is authorized, without further stockholder action, to provide for the
issuance of shares of preferred stock in one or more series, each with such designations, preferences, voting powers (or special,
preferential or no voting powers), relative, participating, optional or other special rights and privileges and such qualifications,
limitations or restrictions thereof, as may be stated in the resolution(s) adopted by our board of directors to create such series.
We may amend from time to time our certificate of incorporation and bylaws to increase the number of authorized shares of common
stock or shares of preferred stock or to make other changes or additions.
We will fix the designations, voting powers,
preferences and rights of the preferred stock of each series we issue under this prospectus, as well as the qualifications, limitations
or restrictions thereof, in the certificate of designation relating to that series. We will file as an exhibit to the registration
statement of which this prospectus is a part, or will incorporate by reference from reports that we file with the SEC, the form
of any certificate of designation that contains the terms of the series of preferred stock we are offering. We will describe in
the applicable prospectus supplement the terms of the series of preferred stock being offered, including, to the extent applicable:
•
the title and stated or par value of the preferred stock;
•
the number of shares of the preferred stock offered, the liquidation preference per share and the offering price of the preferred
stock;
• the
dividend rate(s), period(s) and/or payment date(s) or method(s) of calculation thereof applicable to the preferred stock;
• whether
dividends shall be cumulative or non-cumulative and, if cumulative, the date from which dividends on the preferred stock shall
accumulate;
• the
procedures for any auction and remarketing, if any;
• the
provisions for a sinking fund, if any, for the preferred stock;
• any
voting rights of the preferred stock;
• the
provisions for redemption, if applicable, of the preferred stock;
• any
listing of the preferred stock on any securities exchange or market;
• the
terms and conditions, if applicable, upon which the preferred stock will be convertible into our common stock, including the conversion
price or the manner of calculating the conversion price and conversion period, and any other terms of conversion (including any
anti-dilution provisions, if any);
• whether
the preferred stock will be exchangeable into debt securities, and, if applicable, the exchange price (or how it will be calculated),
the exchange period and any other terms of exchange (including any anti-dilution provisions, if any);
• the
relative ranking and preferences of the preferred stock as to dividend rights and rights upon liquidation, dissolution or winding
up of the affairs of the Company;
• any
material limitations on issuance of any series of preferred stock ranking senior to or on a parity with the series of preferred
stock as to dividend rights and rights upon liquidation, dissolution or winding up of the Company;
• any
other affirmative, negative or other covenants or contractual rights which might be attendant with the specific series of preferred
stock;
• if
appropriate, a discussion of Federal income tax consequences applicable to the preferred stock; and
• any
other specific terms, preferences, rights, limitations or restrictions of the preferred stock.
Certain Anti-Takeover Effects
Provisions of Delaware Law.
We are a Delaware corporation. Section 203 of the DGCL applies to us. It is an anti-takeover statute that is designed to protect
stockholders against coercive, unfair or inadequate tender offers and other abusive tactics and to encourage any person contemplating
a business combination with us to negotiate with our board of directors for the fair and equitable treatment of all stockholders.
Under Section 203 of the DGCL, a Delaware
corporation shall not engage in a “business combination” with an “interested stockholder” for a period
of three years following the date that the stockholder became an interested stockholder. “Business combination” includes
a merger, consolidation, asset sale or other transaction resulting in a financial benefit to the interested stockholder. “Interested
stockholder” is a person who, together with affiliates and associates, owns, or within three years did own, 15% or more of
the corporation’s outstanding voting stock. This prohibition does not apply if:
• prior
to the time that the stockholder became an interested stockholder, the board of directors of the corporation approved either the
business combination or the transaction resulting in the stockholder’s becoming an interested stockholder;
• upon
completion of the transaction resulting in the stockholder’s becoming an interested stockholder, the stockholder owns at
least 85% of the outstanding voting stock of the corporation, excluding voting stock owned by directors who are also officers and
by certain employee stock plans; or
• at
or subsequent to the time that the stockholder became an interested stockholder, the business combination is approved by the board
and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least
two-thirds of the outstanding voting stock that the interested stockholder does not own.
A Delaware corporation may elect not to
be governed by these restrictions. We have not opted out of Section 203.
Classified Board of Directors; Removal
of Directors for Cause.
Our restated certificate of incorporation and amended and restated bylaws provide for our board
of directors to be divided into three classes, as nearly equal in number as possible, serving staggered terms. Approximately one-third
of our board will be elected each year. At each annual meeting of stockholders, directors elected to succeed those directors whose
terms expire will be elected for a three-year term of office. All directors elected to our classified board of directors will serve
until the election and qualification of their respective successors or their earlier resignation or removal. The board of directors
is authorized to create new directorships and to fill such positions so created and is permitted to specify the class to which
any such new position is assigned. The person filling such position would serve for the term applicable to that class. The board
of directors (or its remaining members, even if less than a quorum) is also empowered to fill vacancies on the board of directors
occurring for any reason for the remainder of the term of the class of directors in which the vacancy occurred. Members of the
board of directors may only be removed for cause by either the affirmative vote of a majority of our outstanding voting stock or
the board of directors. These provisions are likely to increase the time required for stockholders to change the composition of
the board of directors. For example, in general, at least two annual meetings will be necessary for stockholders to effect a change
in a majority of the members of the board of directors. The provision for a classified board could prevent a party who acquires
control of a majority of our outstanding common stock from obtaining control of our board of directors until our second annual
stockholders meeting following the date the acquirer obtains the controlling stock interest. The classified board provision could
have the effect of discouraging a potential acquirer from making a tender offer or otherwise attempting to obtain control of us
and could increase the likelihood that incumbent directors will retain their positions.
Advance Notice Procedures.
Our bylaws establish an advance notice procedure for stockholder nominations of persons for election to our board of directors.
Stockholders at an annual meeting will only be able to consider nominations specified in the notice of meeting or brought before
the meeting by or at the direction of our board of directors or by a stockholder who was a stockholder of record on the record
date for the meeting, who is entitled to vote at the meeting and who has given our corporate secretary timely written notice, in
proper form, of the stockholder’s intention to bring that business before the meeting. Although our bylaws will not give
the board of directors the power to approve or disapprove stockholder nominations of candidates or proposals regarding other business
to be conducted at a special or annual meeting, the bylaws may discourage or deter a potential acquirer from conducting a solicitation
of proxies to elect its own slate of directors or otherwise attempting to obtain control of the Company.
Super-Majority Stockholder Vote Required
for Certain Actions.
The Delaware General Corporation Law provides generally that the affirmative vote of a majority of
the shares entitled to vote on any matter is required to amend a corporation's certificate of incorporation or bylaws, unless the
corporation's certificate of incorporation or bylaws, as the case may be, requires a greater percentage. Our restated certificate
of incorporation requires the affirmative vote of the holders of at least 66-2/3% of our outstanding voting stock to amend or repeal
certain provisions of our restated certificate of incorporation. This “super-majority” stockholder vote would be in
addition to any separate class vote that might be required pursuant to the terms of any preferred stock that might then be outstanding.
In addition, our amended and restated bylaws may be amended by the directors then in office.
Effects of Authorized but Unissued
Shares.
We have shares of common stock and “blank check” preferred stock available for future issuance and
may designate and issue preferred stock without stockholder approval, subject to the limitations imposed by the listing standards
of The NASDAQ Global Market or any securities market or exchange our securities may be listed or traded on. Nasdaq Marketplace
Rule 5635(d) requires that an issuer obtain stockholder approval prior to certain issuances of common stock or securities convertible
into or exchangeable for common stock at a price less than the greater of market price or book value of such securities (on an
as exercised basis) if such issuance equals 20% or more of the common stock or voting power of the issuer outstanding before the
transaction. We do not currently intend to engage in any transactions which would require stockholder approval pursuant to Nasdaq
Marketplace Rule 5635(d).
These additional shares may be utilized
for a variety of corporate purposes, including future public offerings to raise additional capital, corporate acquisitions and
employee benefit plans. The existence of authorized but unissued shares of common stock and “blank check” preferred
stock could render more difficult or discourage an attempt to obtain control of a majority of our common stock by means of a proxy
contest, tender offer, merger or otherwise.
Transfer Agent and Registrar
Registrar & Transfer Company is the
transfer agent and registrar for our common stock. The transfer agent and registrar’s address is 10 Commerce Drive, Cranford,
New Jersey 07016-3572.
Listing of Our Common Stock
Our common stock is listed on the NASDAQ
Global Market under the symbol “LAKE."
DESCRIPTION OF DEBT SECURITIES
Subject to any required consents of lenders,
we may offer secured or unsecured debt securities, which may be senior, subordinated or junior subordinated, and which may be convertible.
The debt securities may be issued in one or more series as may be authorized from time to time.
A prospectus supplement will describe the
particular terms of any series of debt we may issue, which may include: title and aggregate principal amount and, if a series,
the total amount authorized and the total amount outstanding as of the most recent practicable date; whether the securities will
be senior, subordinated or junior subordinated; whether the securities will be secured or unsecured; the guarantors, if any, and
the extent of the guarantees (including provisions relating to seniority, subordination, security and release of the guarantees),
if any; whether the securities are convertible into or exchangeable for other securities; the date or dates on which principal
will be payable and maturity date(s); interest rate(s) or the method for determining the interest rate(s); dates on which interest
will accrue or the method for determining dates on which interest will accrue; redemption, early repayment or extension provisions;
material covenants applicable to the particular debt securities being issued; and any other material terms of such debt securities.
The material specific financial, legal and
other terms as well as any material U.S. federal income tax consequences particular to securities of each series will also be described
in the prospectus supplement relating to the securities of that series. The prospectus supplement may or may not modify the general
terms found in this prospectus and will be filed with the SEC. For a complete description of the terms of a particular series of
debt securities, you should read both this prospectus and the prospectus supplement relating to that particular series.
In addition to the debt securities that
may be offered pursuant to this prospectus, we may issue other debt securities in public or private offerings from time to time.
These other debt securities may be issued under other documentation that is not described in this prospectus, and those debt securities
may contain provisions materially different from the provisions applicable to one or more issues of debt securities offered pursuant
to this prospectus.
DESCRIPTION OF WARRANTS
We may issue warrants for the purchase of
shares of our common stock, preferred stock, debt securities and/or units in one or more series together with other securities
or separately, as described in each applicable prospectus supplement. Warrants may be issued independently or together with any
preferred stock, common stock, debt securities, and/or units and may be attached to or separate from any offered securities. Each
series of warrants may be issued under a separate warrant agreement to be entered into between a warrant agent specified in the
agreement and us. The warrant agent, if any, will act solely as our agent in connection with the warrants of that series and will
not assume any obligation or relationship of agency or trust for or with any holders or beneficial owners of warrants. This summary
of some provisions of the warrants is not complete. You should refer to the warrant agreement, including the forms of warrant certificate
representing the warrants if separate from the warrant agreement, relating to the specific warrants being offered for the complete
terms of the warrant agreement and the warrants. The warrant agreement, together with the terms of the warrant certificate and
warrants, will be filed with the SEC in connection with the offering of the specific warrants.
The applicable prospectus supplement will
contain, where applicable, the following terms of and other information relating to the warrants:
|
|
•
|
the title and aggregate number of the warrants;
|
|
|
•
|
the price or prices at which the warrants will be issued and the currency or currencies in which the price of the warrants
may be payable;
|
|
|
•
|
if applicable, the designation and terms of the securities with which the warrants are issued and the number of warrants issued
with each such security or each principal amount of such security;
|
|
|
•
|
in the case of warrants to purchase debt securities, the principal amount of debt securities purchasable upon exercise of one
warrant;
|
|
|
•
|
in the case of warrants to purchase common stock, preferred stock, or units, the number of shares of common stock, preferred
stock, or units, as the case may be, purchasable upon exercise of one warrant;
|
|
|
•
|
the date on which the right to exercise the warrants shall commence and the date on which such right will expire (subject to
any extension);
|
|
|
•
|
whether the warrants will be issued in registered form or bearer form;
|
|
|
•
|
if applicable, the minimum or maximum amount of the warrants which may be exercised at any one time;
|
|
|
•
|
if applicable, the date on and after which the warrants and the related securities will be separately transferable;
|
|
|
•
|
if applicable, the procedures for adjusting the exercise price and number of shares of common stock or preferred stock or units
purchasable upon the exercise of each warrant upon the occurrence of certain events, including stock splits, reverse stock splits,
combinations, subdivisions or reclassifications of common stock or preferred stock;
|
|
|
•
|
the effect of any merger, consolidation, sale or other disposition of our business on the warrant agreement and the warrants;
|
|
|
•
|
the terms of any rights to redeem or call the warrants;
|
|
|
•
|
information with respect to book-entry procedures, if any;
|
|
|
•
|
the terms of the securities issuable upon exercise of the warrants;
|
|
|
•
|
if applicable, a discussion of certain U.S. Federal income tax considerations; and
|
|
|
•
|
any other terms of the warrants, including terms, procedures and limitations relating to the exchange and exercise of the warrants.
|
Transfer Agent and Registrar
Any transfer agent and registrar for any
warrants will be set forth in the applicable prospectus supplement.
DESCRIPTION OF RIGHTS
We may issue rights to purchase our common
stock, preferred stock, debt securities, warrants and/or units. The rights may or may not be transferable by the persons purchasing
or receiving the rights. In connection with any rights offering, we may enter into a standby underwriting or other arrangement
with one or more underwriters or other persons pursuant to which such underwriters or other persons would purchase any offered
securities remaining unsubscribed for after such rights offering. Each series of rights may be issued under a separate rights agent
agreement to be entered into between us and one or more banks, trust companies or other financial institutions, as rights agent,
that we will name in the applicable prospectus supplement. The rights agent, if any, will act solely as our agent in connection
with the rights and will not assume any obligation or relationship of agency or trust for or with any holders of rights certificates
or beneficial owners of rights.
The prospectus supplement and any incorporated
documents relating to any rights that we offer will include specific terms relating to the offering, including, among other matters:
|
|
•
|
the title and aggregate number of the rights;
|
|
|
•
|
the subscription price or a formula for the determination of the subscription price for the rights and the currency or currencies
in which the subscription price may be payable;
|
|
|
•
|
if applicable, the designation and terms of the securities with which the rights are issued and the number of rights issued
with each such security or each principal amount of such security;
|
|
|
•
|
the number or a formula for the determination of the number of the rights issued to each stockholder;
|
|
|
•
|
the extent to which the rights are transferable;
|
|
|
•
|
in the case of rights to purchase debt securities, the principal amount of debt securities purchasable upon exercise of one
right;
|
|
|
•
|
in the case of rights to purchase common stock, preferred stock, warrants and/or units, the number of shares of common stock,
preferred stock, warrants and/or units, as the case may be, purchasable upon exercise of one right;
|
|
|
•
|
the date on which the right to exercise the rights would commence and the date on which the rights shall expire (subject to
any extension);
|
|
|
•
|
if applicable, the minimum or maximum amount of the rights which may be exercised at any one time;
|
|
|
•
|
the extent to which such rights include an over-subscription privilege with respect to unsubscribed securities;
|
|
|
•
|
if applicable, the procedures for adjusting the exercise price and number of shares of common stock or preferred stock purchasable
upon the exercise of each right upon the occurrence of certain events, including stock splits, reverse stock splits, combinations,
subdivisions or reclassifications of common stock or preferred stock;
|
|
|
•
|
the effect of any merger, consolidation, sale or other disposition of our business on the rights;
|
|
|
•
|
the terms of any rights to redeem or call the rights;
|
|
|
•
|
information with respect to book-entry procedures, if any;
|
|
|
•
|
the terms of the securities issuable upon exercise of the rights;
|
|
|
•
|
if applicable, the material terms of any standby underwriting, backstop or other purchase arrangement that we may enter into
in connection with the rights offering;
|
|
|
•
|
if applicable, a discussion of certain U.S. Federal income tax considerations; and
|
|
|
•
|
any other terms of the rights, including terms, procedures and limitations relating to the exchange and exercise of the rights.
|
Each right would entitle the holder of the
rights to purchase such principal amount of securities or shares of stock at the subscription price as shall in each case be set
forth in, or be determinable as set forth in, the prospectus supplement relating to the rights offered thereby. Rights may be exercised
at any time up to the close of business on the expiration date for the rights provided in the prospectus supplement relating to
the rights offered thereby. After the close of business on the expiration date, all unexercised rights will become void.
If less than all of the rights issued in
any rights offering are exercised, we may offer any unsubscribed securities directly to persons other than our security holders,
to or through agents, underwriters or dealers or through a combination of such methods, including pursuant to standby arrangements,
as described in the applicable prospectus supplement.
DESCRIPTION OF UNITS
We may issue units consisting of any combination
of the other types of securities offered under this prospectus in one or more series. We may evidence each series of units by unit
certificates that we will issue under a separate agreement. We may enter into unit agreements with a unit agent. Each unit agent
will be a bank or trust company that we select. We will indicate the name and address of the unit agent in the applicable prospectus
supplement relating to a particular series of units.
The following description, together with
the additional information included in any applicable prospectus supplement, summarizes the general features of the units that
we may offer under this prospectus. You should read any prospectus supplement and any free writing prospectus that we may authorize
to be provided to you related to the series of units being offered, as well as the complete unit agreements that contain the terms
of the units. Specific unit agreements will contain additional important terms and provisions and we will file as an exhibit to
the registration statement of which this prospectus is a part, or will incorporate by reference from another report that we file
with the SEC, the form of each unit agreement relating to units offered under this prospectus.
If we offer any units, certain terms of
that series of units will be described in the applicable prospectus supplement, including, without limitation, the following, as
applicable:
|
|
•
|
the title of the series of units;
|
|
|
•
|
identification and description of the separate constituent
securities comprising the units;
|
|
|
•
|
the price or prices at which the units will be issued;
|
|
|
•
|
the date, if any, on and after which the constituent
securities comprising the units will be separately transferable;
|
|
|
•
|
a discussion of certain United States federal income
tax considerations applicable to the units; and
|
|
|
•
|
any other terms of the units and their constituent securities.
|
PLAN OF DISTRIBUTION
We may sell the securities covered by this
prospectus from time to time in one or more offerings. Registration of the securities covered by this prospectus does not mean,
however, that those securities will necessarily be offered or sold.
We may sell our securities, separately or
together, in any one or more of the following ways:
|
|
•
|
directly to investors, including through a specific bidding,
auction or other process;
|
|
|
•
|
to investors through agents;
|
|
|
•
|
to or through brokers or dealers;
|
|
|
•
|
to the public through underwriting syndicates led by
one or more managing underwriters;
|
|
|
•
|
in “at the market” offerings, within the
meaning of Rule 415(a)(4) of the Securities Act or through a market maker or into an existing trading market on an exchange or
otherwise;
|
|
|
•
|
to one or more underwriters for resale to investors or
to the public; and
|
|
|
•
|
through any combination of the foregoing.
|
Sales of securities may be effected from
time to time in one or more transactions, including negotiated transactions:
|
|
•
|
at a fixed price or prices, which may be changed;
|
|
|
•
|
at market prices prevailing at the time of sale;
|
|
|
•
|
at prices related to prevailing market prices; or
|
We will describe the method of distribution
of the securities and the terms of the offering in the prospectus supplement. Any discounts or concessions allowed or re-allowed
or paid to dealers may be changed from time to time.
Sale Through Underwriters or Dealers
Only underwriters named in the prospectus
supplement are underwriters of the securities offered by the prospectus supplement.
If underwriters are used in the sale, the
underwriters will acquire the securities for their own account, including through underwriting, purchase, security lending or repurchase
agreements with us. The underwriters may resell the securities from time to time in one or more transactions, including negotiated
transactions. Underwriters may sell the securities in order to facilitate transactions in any of our other securities (described
in this prospectus or otherwise), including other public or private transactions and short sales. Underwriters may offer securities
to the public either through underwriting syndicates represented by one or more managing underwriters or directly by one or more
firms acting as underwriters. Unless otherwise indicated in the prospectus supplement, the obligations of the underwriters to purchase
the securities will be subject to certain conditions, and the underwriters will be obligated to purchase all the offered securities
if they purchase any of them. The underwriters may change from time to time any initial public offering price and any discounts
or concessions allowed or reallowed or paid to dealers.
If dealers are used in the sale of securities
offered through this prospectus, we will sell the securities to them as principals. They may then resell those securities to the
public at varying prices determined by the dealers at the time of resale. The prospectus supplement will include the names of the
dealers and the terms of the transaction.
In compliance with the guidelines of the
Financial Industry Regulatory Authority, the maximum compensation to the underwriters or dealers in connection with the sale of
our securities pursuant to this prospectus and the accompanying supplement to this prospectus may not exceed 8% of the aggregate
offering price of the securities as set forth on the cover page of any prospectus supplement.
Direct Sales and Sales Through Agents
We may sell the securities offered through
this prospectus directly. In this case, no underwriters or agents would be involved. Such securities may also be sold through agents
designated from time to time. The prospectus supplement will name any agent involved in the offer or sale of the offered securities
and will describe any commissions payable to the agent. Unless otherwise indicated in the prospectus supplement, any agent will
agree to use its reasonable best efforts to solicit purchases for the period of its appointment.
We may sell the securities directly to institutional
investors or others who may be deemed to be underwriters within the meaning of the Securities Act with respect to any sale of those
securities. The terms of any such sales will be described in the prospectus supplement.
Delayed Delivery Contracts
If the prospectus supplement indicates,
we may authorize agents, underwriters or dealers to solicit offers from certain types of institutions to purchase securities at
the public offering price under delayed delivery contracts. These contracts would provide for payment and delivery on a specified
date in the future. The contracts would be subject only to those conditions described in the prospectus supplement. The applicable
prospectus supplement will describe the commission payable for solicitation of those contracts.
Market Making, Stabilization and Other
Transactions
Our common stock is listed on The NASDAQ
Global Market. Any common stock sold pursuant to a prospectus supplement will be eligible for listing and trading on Nasdaq, subject
to official notice of issuance. Unless the applicable prospectus supplement states otherwise, each series of preferred stock, series
of warrants, or other securities will be a new issue and will have no established trading market. The applicable prospectus supplement
will indicate if we elect to list a series of warrants on an exchange. Any underwriters that we use in the sale of securities may
make a market in such securities, but may discontinue such market making at any time without notice. Therefore, we cannot assure
you that the securities will have a liquid trading market.
Certain persons participating in an offering
may engage in overallotment, stabilizing transactions, syndicate covering transactions and penalty bids in accordance with rules
and regulations under the Exchange Act. Overallotment involves the sale in excess of the offering size, which create a short position.
Stabilizing transactions involve bids to purchase the underlying security in the open market for the purpose of pegging, fixing
or maintaining the price of the securities. Syndicate covering transactions involve purchases of the securities in the open market
after the distribution has been completed in order to cover syndicate short positions.
Penalty bids permit the underwriters to
reclaim a selling concession from a syndicate member when the securities originally sold by the syndicate member are purchased
in a syndicate covering transaction to cover syndicate short positions. Stabilizing transactions, syndicate covering transactions
and penalty bids may cause the price of the securities to be higher than it would be in the absence of the transactions. The underwriters
may, if they commence these transactions, discontinue them at any time.
General Information
Agents, underwriters,
and broker-dealers may be entitled, under agreements entered into with us, to indemnification by us against certain liabilities,
including liabilities under the Securities Act. Our agents, underwriters, and broker-dealers, or their affiliates, may be customers
of, engage in transactions with or perform services for us, in the ordinary course of business.
LEGAL MATTERS
The validity of the securities being offered
hereby will be passed upon for us by Moomjian, Waite & Coleman, LLP, Jericho, New York.
EXPERTS
Our consolidated financial statements
as of and for the fiscal years ended January 31, 2016 and January 31, 2015 incorporated in this prospectus by reference from
our Annual Report on Form 10-K, as amended on Forms 10-K/A, for the fiscal year ended January 31, 2016, have been audited by
Mazars USA LLP (formerly WeiserMazars LLP), an independent registered public accounting firm, as stated in its report, which
is incorporated herein by reference, and the financial statements for our subsidiary Lakeland Brasil S.A. as of and for the
fiscal year ended January 31, 2015 have been audited by Mazars Auditores Independentes, as stated in its report, which is
incorporated herein by reference, and the financial statements for each of our subsidiaries Weifang Lakeland Safety Products
Co., Ltd. and Lakeland (Beijing) Safety Products Co., Ltd. as of and for the fiscal years ended January 31, 2016 and January
31, 2015 have been audited by Shanghai Mazars Certified Public Accountants, as stated in its reports, each of which is
incorporated herein by reference. Such financial statements are incorporated by reference in reliance upon the
respective report of each such firm given upon their authority as experts in accounting and auditing.
WHERE YOU CAN FIND MORE INFORMATION
We have filed with the SEC a registration
statement under the Securities Act with respect to the securities offered hereby. This prospectus, which constitutes a part of
the registration statement, does not contain all of the information in the registration statement. For further information about
us and the securities offered hereby, see the registration statement and the exhibits and schedules thereto. We are subject to
the informational requirements of the Exchange Act, and, in accordance therewith, we file unaudited quarterly and audited annual
reports, proxy statements and other information with the SEC. You may read and copy all or a portion of the reports, proxy statements
and other information we file at the SEC’s principal office in Washington, D.C., and copies of all or any part thereof may
be obtained from the public reference facilities maintained by the SEC at 100 F Street, N.E., Washington, D.C. 20549, after payment
of fees prescribed by the SEC. Please call the SEC at l-800-SEC-0330 for further information on operation of the public reference
rooms. The SEC also maintains an Internet site which provides online access to reports, proxy statements and other information
regarding registrants that file electronically with the SEC at the address
http://www.sec.gov
. In addition, we post our
filed documents on our website at
http://www.lakeland.com
. Except for the documents incorporated by reference into this
prospectus, the information on Lakeland’s website is not a part of this prospectus.
INCORPORATION OF CERTAIN INFORMATION
BY REFERENCE
The SEC allows us to “incorporate
by reference” information into this prospectus. This means that we can disclose important information to you by referring
you to other documents we have filed separately with the SEC, without actually including the specific information in this prospectus
or any prospectus supplement. The information incorporated by reference is considered to be part of this prospectus and any applicable
prospectus supplement, and information that we file later with the SEC will automatically update, and may supersede, information
in this prospectus and any prospectus supplement.
We are incorporating by reference the following
documents:
|
|
•
|
our Annual Report on Form 10-K for the fiscal year ended January 31, 2016 filed with the SEC on April 21, 2016, as amended
by Form 10-K/A filed with the SEC on each of February 17, 2017 and March 10, 2017;
|
|
|
•
|
our Quarterly Report on Form 10-Q for the fiscal quarter ended April 30, 2016 filed with the SEC on June 14, 2016;
|
|
|
•
|
our Quarterly Report on Form 10-Q for the fiscal quarter ended July 31, 2016 filed with the SEC on September 14, 2016;
|
|
|
•
|
our Quarterly Report on Form 10-Q for the fiscal quarter ended October 31, 2016 filed with the SEC on December 14, 2016, as
amended by Form 10-Q/A filed with the SEC on December 15, 2016;
|
|
|
•
|
our Current Reports on Form 8-K filed with the SEC on April 21, 2016, June 14, 2016, June 16, 2016, July 19, 2016, July 25,
2016, September 14, 2016, December 14, 2016, December 14, 2016, and March 10, 2017; and
|
|
|
•
|
the description of our common stock contained in our Registration Statement on Form 8-A, dated March 30, 1987, including any
amendment(s) or report(s) filed for the purpose of updating such description.
|
We are also incorporating by reference any
future filings made by us with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act after (i) the date of the initial
filing of the registration statement and prior to effectiveness of the registration statement, and (ii) the date of this prospectus
and before all securities to which this prospectus relates have been sold or the offering is otherwise terminated; provided, however,
that notwithstanding the forgoing, unless specifically stated to the contrary, none of the information that is not deemed “filed”
with the SEC, including information furnished under Items 2.02 and 7.01 of any Current Report on Form 8-K, will be incorporated
by reference into, or otherwise included in, this prospectus.
You may request a copy of any of the documents
that we incorporate by reference into this prospectus at no cost by writing or telephoning us at the following address:
Lakeland Industries, Inc.
3555 Veterans Memorial Highway, Suite C
Ronkonkoma, NY 11779
Attn: Christopher J. Ryan, Secretary
(631) 981-9700
CJRyan@lakeland.com
Any statements contained in a document incorporated
by reference in this prospectus shall be deemed to be modified or superseded for purposes of this prospectus to the extent that
a statement contained in this prospectus (or in any other subsequently filed document which also is incorporated by reference in
this prospectus) modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed to constitute
a part of this prospectus except as so modified or superseded.
SEC POSITION ON INDEMNIFICATION FOR SECURITIES
ACT LIABILITIES
Our restated certificate of incorporation
requires that we indemnify our directors and officers for certain liabilities incurred in the performance of their duties on our
behalf. We have also entered into indemnification agreements with each of our directors and executive officers which require us,
among other things, to indemnify them against certain liabilities which may arise by reason of their status or service as a director
or officer (other than liabilities arising from willful misconduct of a culpable nature). Insofar as indemnification for liabilities
arising under the Securities Act may be permitted to directors, officers and controlling persons as provided in the foregoing provisions,
or otherwise, we have been advised that in the opinion of the SEC such indemnification is against public policy as expressed in
the Securities Act and is therefore unenforceable.
PROSPECTUS DATED ___________, 2017
LAKELAND INDUSTRIES, INC.
Common Stock
Preferred Stock
Debt Securities
Warrants
Rights
Units
PROSPECTUS
The issuer has not authorized any dealer, salesperson or other
person to give you written information other than this prospectus or to make representations as to matters not stated in this prospectus.
You must not rely on unauthorized information. This prospectus is not an offer to sell these securities or the issuer's solicitation
of your offer to buy the securities in any jurisdiction where that would not be permitted or legal. Neither the delivery of this
prospectus nor any sales made hereunder after the date of this prospectus shall create an implication that the information contained
herein or the affairs of our Company have not changed since the date hereof.
PART II
INFORMATION NOT REQUIRED IN PROSPECTUS
|
|
Item 14.
|
Other Expenses of Issuance and Distribution
|
|
Securities and Exchange Commission registration fee
|
|
$
|
3,477
|
|
|
Listing fees
|
|
|
|
(1)
|
|
Legal fees and expenses
|
|
|
|
(1)
|
|
Accounting fees and expenses
|
|
|
|
(1)
|
|
Transfer agent and registrar fees
|
|
|
|
(1)
|
|
Printing expenses and Miscellaneous
|
|
|
|
(1)
|
|
Total
|
|
$
|
|
(1)
|
(1)
These
fees will be dependent on the type of securities offered and number of offerings and, therefore, cannot be estimated at this time.
Additional information regarding estimated fees and expenses will be provided at the time information as to an offering is included
in a prospectus supplement.
|
|
Item 15.
|
Indemnification of Directors and Officers
|
Section 102(b)(7) of the Delaware General
Corporation Law, or DGCL, enables a Delaware corporation to provide in its certificate of incorporation for the elimination or
limitation of the personal liability of a director to the corporation or its stockholders for monetary damages for breach of fiduciary
duty as a director. However, no such provision can eliminate or limit a director's liability for any breach of the director's duty
of loyalty to the corporation or its stockholders, for acts or omissions not in good faith or which involve intentional misconduct
or a knowing violation of law, for unlawful payment of dividends or unlawful stock purchase or redemption, or for any transaction
from which the director derives an improper personal benefit.
Section 145 of the DGCL authorizes
a corporation to indemnify any person who was or is a party, or is threatened to be made a party, to any threatened, pending or
completed action, suit or proceeding, whether civil, criminal, administrative or investigative, by reason of the fact that the
person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation
as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against
expenses, including attorneys' fees, judgments, fines and amounts paid in settlement actually and reasonably incurred by the person
in connection with such action, suit or proceeding, if the person acted in good faith and in a manner the person reasonably believed
to be in, or not opposed to, the best interests of the corporation and, with respect to any criminal action or proceeding, had
no reasonable cause to believe the person's conduct was unlawful. In addition, the DGCL does not permit indemnification in any
threatened, pending or completed action or suit by or in the right of the corporation in respect of any claim, issue or matter
as to which such person shall have been adjudged to be liable to the corporation, unless the court in which such action or suit
was brought shall determine upon application that, despite the adjudication of liability, but in view of all the circumstances
of the case, such person is fairly and reasonably entitled to indemnity for such expenses, which such court shall deem proper.
To the extent that a present or former director or officer of a corporation has been successful on the merits or otherwise in defense
of any action, suit or proceeding referred to above, or in defense of any claim, issue or matter, such person shall be indemnified
against expenses, including attorneys' fees, actually and reasonably incurred by such person. Indemnity is mandatory to the extent
a claim, issue or matter has been successfully defended.
These provisions will not limit the liability
of directors or officers under the federal securities laws of the United States.
Our Restated Certificate of Incorporation
provides for the indemnification of directors and officers to the fullest extent permissible under Delaware law.
We have entered into an indemnification
agreement with each of our directors and executive officers which requires us, among other things, to indemnify them against certain
liabilities which may arise by reason of his status or service as a director or officer (other than liabilities arising from willful
misconduct of a culpable nature). We also intend to maintain director and officer liability insurance, if available on reasonable
terms.
Reference is made to the Exhibit Index filed
as part of this registration statement. All exhibits have been previously filed unless otherwise noted.
|
|
(a)
|
The undersigned Registrant hereby undertakes:
|
(1) To
file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:
(i) To include
any prospectus required by Section 10(a)(3) of the Securities Act of 1933;
(ii) To reflect
in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective
amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the
Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar
value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated
maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in
the aggregate, the changes in volume and price represent no more than 20 percent change in the maximum aggregate offering
price set forth in the "Calculation of Registration Fee" table in the effective registration statement;
(iii) To
include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement
or any material change to such information in the Registration Statement;
Provided, however,
that paragraphs (i), (ii),
and (iii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained
in reports filed with or furnished to the Securities and Exchange Commission by the Registrant pursuant to Section 13 or Section
15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the Registration Statement, or is contained
in a form of prospectus filed pursuant to Rule 424(b) that is part of the Registration Statement.
(2) That,
for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed
to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time
shall be deemed to be the initial
bona fide
offering thereof.
(3) To
remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the
termination of the offering.
(4) That,
for the purpose of determining liability under the Securities Act of 1933 to any purchaser:
(i) If
the registrant is relying on Rule 430B:
(A) Each
prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as
of the date the filed prospectus was deemed part of and included in the registration statement; and
(B) Each
prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance
on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii), or (x) for the purpose of providing
the information required by Section 10(a) of the Securities Act of 1933 shall be deemed to be part of and included in the
registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the
first contract of sale of securities in the offering described in the prospectus. As provided in Rule 430B, for liability
purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date
of the registration statement relating to the securities in the registration statement to which that prospectus relates, and the
offering of such securities at that time shall be deemed to be the initial
bona fide
offering thereof.
Provided,
however,
that no statement made in a registration statement or prospectus that is part of the registration statement or made
in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the
registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify
any statement that was made in the registration statement or prospectus that was part of the registration statement or made in
any such document immediately prior to such effective date.
(ii) If
the registrant is subject to Rule 430C, each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating
to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A,
shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness. Provided,
however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in
a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration
statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that
was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately
prior to such date of first use.
(5) That,
for the purpose of determining liability of the registrant under the Securities Act of 1933 to any purchaser in the initial distribution
of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant
pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if
the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant
will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:
(i) Any
preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424;
(ii) Any
free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to
by the undersigned registrant;
(iii) The
portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant
or its securities provided by or on behalf of the undersigned registrant; and
(iv) Any
other communication that is an offer in the offering made by the undersigned registrant to the purchaser.
(b) The registrant
hereby undertakes that, for the purpose of determining liability of the registrant under the Securities Act of 1933, each filing
of the registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Securities Exchange Act of
1934 (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to section 15(d) of the
Securities Exchange Act of 1934) that is incorporated by reference in the registration statement shall be deemed to be a new
registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed
to be the initial
bona fide
offering thereof.
(c) In the event that
rights or warrants are to be offered to existing security holders and any securities not taken by the security holders are to be
offered to the public, the undersigned registrant hereby undertakes to supplement the prospectus, after the expiration of the subscription
period, to set forth the results of the subscription offer, the transactions by the underwriters during the subscription period,
the amount of unsubscribed securities to be purchased by the underwriters and the terms of any subsequent reoffering thereof. If
any public offering by the underwriters is to be made on terms differing from those set forth on the cover page of the prospectus,
a post-effective amendment will be filed to set forth the terms of such offering.
(d) Insofar as indemnification
for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the
registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities
and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable.
In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred
or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding)
is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant
will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate
jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act of 1933
and will be governed by the final adjudication of such issue.
(e) If and when applicable,
the undersigned registrant hereby undertakes to file an application for the purpose of determining the eligibility of the Trustee
to act under subsection (a) of Section 310 of the Trust Indenture Act in accordance with the rules and regulations prescribed by
the Commission under Section 305(b)(2) of such Act.
SIGNATURES
Pursuant to the requirements of the Securities
Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing
on Form S-3 and has duly caused this Registration Statement on Form S-3 to be signed on its behalf by the undersigned, thereunto
duly authorized, in the City of Ronkonkoma, State of New York, on March 24, 2017.
|
|
LAKELAND INDUSTRIES, INC.
|
|
|
|
|
|
|
By:
|
/s/ Christopher J. Ryan
|
|
|
Name:
|
Christopher J. Ryan
|
|
|
Title:
|
Chief Executive Officer and President
|
POWER OF ATTORNEY
Pursuant to the requirements of the Securities
Act of 1933, this Registration Statement has been signed by the following persons in the capacities indicated on March 24, 2017.
Each person whose signature appears below constitutes and appoints Christopher J. Ryan or Teri W. Hunt, and each of them, with
full power of substitution, his or her true and lawful attorney-in-fact and agent to do any and all acts and things in his or her
name and on his or her behalf in his or her capacity indicated below which they or either of them may deem necessary or advisable
to enable Lakeland Industries, Inc. to comply with the Securities Act of 1933, as amended, and any rules, regulations and requirements
of the Securities and Exchange Commission, in connection with this Registration Statement including specifically, but not limited
to, power and authority to sign for him or her in his or her name in the capacities stated below, any and all amendments (including
post-effective amendments) thereto, granting unto said attorney-in-fact and agent full power and authority to do and perform each
and every act and thing requisite and necessary to be done in such connection, as fully to all intents and purposes as he or she
might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his or her substitute
or substitutes, may lawfully do or cause to be done by virtue thereof.
|
Signature
|
|
Title
|
|
|
|
|
|
/s/ Christopher J. Ryan
Christopher J. Ryan
|
|
Chief Executive Officer and President (Principal Executive Officer) and Director
|
|
|
|
|
|
/s/ Teri W. Hunt
Teri W. Hunt
|
|
Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)
|
|
|
|
|
|
/s/ Alfred John Kreft
Alfred John Kreft
|
|
Chairman of the Board of Directors
|
|
|
|
|
|
/s/ James M. Jenkins
James M. Jenkins
|
|
Director
|
|
|
|
|
|
/s/ Stephen M. Bachelder
Stephen M. Bachelder
|
|
Director
|
|
|
|
|
|
/s/ Thomas J. McAteer
Thomas J. McAteer
|
|
Director
|
EXHIBIT INDEX
|
Exhibit No.
|
|
Description
|
|
1.1*
|
|
Form of Underwriting Agreement.
|
|
4.1
|
|
Restated Certificate of Incorporation of Lakeland Industries, Inc. (incorporated by reference to Exhibit 3.2 of Registrant’s Quarterly Report on Form 10-Q filed December 7, 2011).
|
|
4.2
|
|
Amended and Restated Bylaws of Lakeland Industries, Inc. (incorporated by reference to Exhibit 3.1 of Registrant’s Form 8-K filed December 14, 2016).
|
|
4.3
|
|
Specimen Certificate for Shares of Common Stock (incorporated by reference to Registration Statement on Form 8-A, dated March 30, 1987).
|
|
4.4*
|
|
Form of Certificate of Designation of Preferred Stock and Preferred Stock Certificate.
|
|
4.5*
|
|
Form of Debt Securities.
|
|
4.6*
|
|
Form of Warrant Agreement and Warrant Certificate.
|
|
4.7*
|
|
Form of Rights Agent Agreement (including form of Rights Certificate).
|
|
4.8*
|
|
Form of Unit Agreement and Unit Certificate.
|
|
5.1**
|
|
Opinion of Moomjian, Waite & Coleman, LLP.
|
|
23.1**
|
|
Consent of Mazars USA LLP (formerly WeiserMazars LLP).
|
|
23.2**
|
|
Consent of Mazars Auditores Independentes.
|
|
23.3**
|
|
Consent of Shanghai Mazars Certified Public Accountants
|
|
23.4**
|
|
Consent of Shanghai Mazars Certified Public Accountants
|
|
23.5
|
|
Consent of Moomjian, Waite & Coleman, LLP (included in Exhibit 5.1).
|
|
24
|
|
Power of Attorney (included in the signature page).
|
________________
|
|
*
|
To be filed by amendment to this registration statement
or as an exhibit to a report filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, and incorporated
herein by reference, if applicable.
|
Lakeland Industries (NASDAQ:LAKE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Lakeland Industries (NASDAQ:LAKE)
Historical Stock Chart
From Apr 2023 to Apr 2024
